Literature DB >> 19042918

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Paola Guglielmelli, Giovanni Barosi, Lisa Pieri, Elisabetta Antonioli, Alberto Bosi, Alessandro M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19042918      PMCID： PMC2625425          DOI： 10.3324/haematol.13721

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Authors:  Francesco Passamonti; Elisa Rumi; Daniela Pietra; Matteo G Della Porta; Emanuela Boveri; Cristiana Pascutto; Laura Vanelli; Luca Arcaini; Sara Burcheri; Luca Malcovati; Mario Lazzarino; Mario Cazzola
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

2.  Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.

Authors:  A M Vannucchi; E Antonioli; P Guglielmelli; G Longo; A Pancrazzi; V Ponziani; C Bogani; P R Ferrini; A Rambaldi; V Guerini; A Bosi; T Barbui
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

3.  Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.

Authors:  A Tefferi; T L Lasho; J Huang; C Finke; R A Mesa; C Y Li; W Wu; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

4.  Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.

Authors:  Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Vittoria Guerini; Giovanni Barosi; Marco Ruggeri; Giorgina Specchia; Francesco Lo-Coco; Federica Delaini; Laura Villani; Silvia Finotto; Emanuele Ammatuna; Renato Alterini; Valentina Carrai; Gloria Capaccioli; Simonetta Di Lollo; Vincenzo Liso; Alessandro Rambaldi; Alberto Bosi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

5.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

Authors:  Peter J Campbell; Martin Griesshammer; Konstanze Döhner; Hartmut Döhner; Rajko Kusec; Hans C Hasselbalch; Thomas Stauffer Larsen; Niels Pallisgaard; Stéphane Giraudier; Marie-Caroline Le Bousse-Kerdilès; Christophe Desterke; Bernadette Guerton; Brigitte Dupriez; Dominique Bordessoule; Pierre Fenaux; Jean-Jacques Kiladjian; Jean-François Viallard; Jean Brière; Claire N Harrison; Anthony R Green; John T Reilly
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

6.  Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

Authors:  Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

7.  The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Authors:  Ayalew Tefferi; Terra L Lasho; Susan M Schwager; David P Steensma; Ruben A Mesa; Chin-Yang Li; Martha Wadleigh; D Gary Gilliland
Journal:  Br J Haematol       Date:  2005-11       Impact factor: 6.998

8.  Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.

Authors:  Elisabetta Antonioli; Paola Guglielmelli; Giada Poli; Costanza Bogani; Alessandro Pancrazzi; Giovanni Longo; Vanessa Ponziani; Lorenzo Tozzi; Lisa Pieri; Valeria Santini; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

9.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

10.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528
View more
  10 in total

1.  JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Authors:  Andreas Kreft; Thomas Kindler; Erik Springer; Charles James Kirkpatrick
Journal:  Virchows Arch       Date:  2011-10-18       Impact factor: 4.064

Review 2.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

3.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

4.  The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Authors:  Grzegorz Helbig; Agata Wieczorkiewicz; Krzysztof Woźniczka; Katarzyna Wiśniewska-Piąty; Anna Rusek; Sławomira Kyrcz-Krzemień
Journal:  Med Oncol       Date:  2012-03-01       Impact factor: 3.064

5.  The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Montse Gómez; Concepción Boqué; Francisca Ferrer-Marín; José-María Raya; Valentín García-Gutiérrez; Ana Kerguelen; Blanca Xicoy; Pere Barba; Jesús Martínez; Elisa Luño; Alberto Alvarez-Larrán; Joaquín Martínez-López; Elisa Arbelo; Carles Besses
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

6.  Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Authors:  Lucia Masarova; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Kate J Newberry; Taghi Manshouri; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-06-02       Impact factor: 3.156

7.  A rare der(Y)t(Y;1)(q12;q12) in a patient with post-polycythemic myelofibrosis: a case report.

Authors:  Masahiro Manabe; Osami Takeda; Junya Okita; Teruhito Takakuwa; Naonori Harada; Hirofumi Nakano; Shuichiro Okamoto; Yasutaka Aoyama; Takeo Kumura; Tadanobu Ohta; Yoshio Furukawa; Atsuko Mugitani
Journal:  Am J Blood Res       Date:  2013-05-05

Review 8.  Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.

Authors:  Amy Zhou; Amber Afzal; Stephen T Oh
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

9.  The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms.

Authors:  Ipek Yonal-Hindilerden; Aynur Daglar-Aday; Basak Akadam-Teker; Ceylan Yilmaz; Meliha Nalcaci; Akif Selim Yavuz; Deniz Sargin
Journal:  J Clin Med Res       Date:  2014-12-29

Review 10.  Guidelines for the management of myeloproliferative neoplasms.

Authors:  Chul Won Choi; Soo-Mee Bang; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Soo-Jeong Kim; Yeo-Kyeoung Kim; Jinny Park; Jong-Ho Won
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.